Guardant Health Reports Strong Q3 2026 Growth Driven by Oncology and Screening Segments
Guardant Health (GH) reported significant third-quarter growth for 2026, with total revenue reaching $361 million, a 36% increase year-over-year. This surge was fueled by robust performance in the oncology segment, which saw a 58% increase in test volume, and an explosive 180% rise in screening revenue driven by the Shield platform. The company demonstrated improved operational efficiency, noting that the cost per Shield test dropped to $330, beating internal targets ahead of schedule. While reporting a non-GAAP net loss per share of $0.29, this represents an improvement over the previous year's loss. Management raised full-year revenue guidance and highlighted expanded coverage for Shield, now reaching 100 million covered lives. Despite the positive momentum, CFO Mike Bell noted potential short-term cash flow impacts due to a timing shift in CMS government payments expected to move into early 2027. However, with $1.1 billion in cash and investments, the company maintains strong liquidity for ongoing operations.
Topics: financial results full-year guidance oncology revenue screening segment growth